PTPN9表达水平与结直肠癌的临床关系研究

doi:10.11904/j.issn.1002-3070.2019.05.006

Abstract

Abstract: Objective The aim of this study was to investigate the expression of PTPN9 in colorectal cancer and its relationship with various clinical indicators.Methods A retrospective study of 146 patients with colorectal cancer who had a clear pathology and complete clinical data from December 2007 to December 2008 at Harbin Medical University Cancer Hospital was performed.Tumor tissues from 132 patients and non-cancerous tissues from 14 patients were randomly selected for determination of PTPN9 protein by immunohistochemistry,and double-blind scores were performed by two senior pathologists.According to the staining score,the clinical indicators such as age,gender,gross morphology,degree of differentiation and prognosis were compared.Survival analysis was performed by Kaplan-Meier curve using Cox proportional hazard model for multivariate analysis.Results The expression of PTPN9 in tumor tissues was statistically different from non-tumor tissues(P=0.009).There was a relationship between PTPN9 expression and N stage(P=0.021),M stage(P=0.022),pathological stage(P=0.008),clinical indicators such as diabetes(P=0.022)and survival(P=0.001).High expression of PTPN9 would result in a decrease overall survival in patients with colorectal cancer(P＜0.001).Multivariate Cox regression analysis showed that the expression of PTPN9 was one of the independent risk factors affecting the prognosis of patients with colorectal cancer(HR=1.202,P＜0.05).Conclusion The expression of PTPN9 is significantly different between cancer tissues and non-cancerous tissues,and the expression of PTPN9 is higher in cancer tissues.As the expression of PTPN9 was increased,the pathological stage of tumors was also increased.The high expression of PTPN9 is a correlation with the onset of diabetes and also leads to a decrease in overall survival of patients with colorectal cancer.

Key words: Colorectal, PTPN9, Tumor stage, Prognosis

CLC Number:

R735.3+5

XIA Tianyi, ZHANG Bomiao, YAO Kefei, CUI Binbin. Clinical relationship between PTPN9 expression and colorectal cancer[J]. Journal of Practical Oncology, 2019, 33(5): 415-419.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2019.05.006

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2019/V33/I5/415

References

1 Torre LA,Bray F,Siegel RL,et al.Global cancer statistic,2012[J].CA Cancer J Clin,2015,65(2):87-108.
2 Hunter T.Signaling-2000 and beyond[J].Cell,2000,100(1):113-127.
3 Sato Y,Arai H,Miyata A,et al.Primary structure of alpha-tocopherol transfer protein from rat liver.Homology with cellular retinaldehyde-binding protein[J].J Biol Chem,1993,268(24):17705-17710.
4 Zhu J,Li H,Ma J,et al.PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126[J].Oncol Lett,2017,14(2):1419-1426.
5 Hu B,Yan X,Liu F,et al.Downregulated expression of PTPN9 contributes to human hepatocellular carcinoma growth and progression[J].Pathol Oncol Res,2016,22(3):555-565.
6 Hong Y,Liang H,Uzair-Ur-Rehman,et al.miR-96 promotes cell proliferation,migration and invasion by targeting PTPN9 in breast cancer[J].Sci Rep,2016,6:37421.
7 Sun T,Aceto N,Meerbrey KL,et al.Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase[J].Cell,2011,144(5):703-718.
8 Su F,Ren F,Rong Y,et al.Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer[J].Breast Cancer Res,2012,14(2):38.
9 Gong W,Wang L,Yao JC,et al.Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer[J].Clin Cancer Res,2005,11(4):1386-1393.
10 Niu G,Wright KL,Huang M,et al.Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis[J].Oncogene,2002,21(13):2000-2008.
11 Hao Q,Samten B,Ji HL,et al.Tyrosine phosphatase PTP-MEG2 negatively regulates vascular endothelial growth factor receptor signaling and function in endothelial cells[J].Am J Physiol Cell Physiol,2012,303(5):C548-553.
12 Chatterjee S,Heukamp LC,Siobal M,et al.Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer[J].J Clin Invest,2013,123(4):1732-1740.
13 Charles C,Koo S,Wang Y,et al.Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling[J].Cell Metab,2006,3(5):367-378.
14 Mashili F,Chibalin AV,Krook A,et al.Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes[J].Diabetes,2013,62(2):457-465.

[1]	LIU Siwei, CUI Yue, SUN Yuanyuan, HU Jing, ZHANG Wenrui, CAO Mengru. Effect of FOXD3 in lung cancer cells [J]. Journal of Practical Oncology, 2019, 33(5): 390-396.
[2]	ZHANG Yiwei, SHI Jing, LIU Yupeng, CAO Liming, HU Fulan, ZHAO Yashuang. Relationship between methylation of USP1 gene in peripheral blood and prognosis risk of colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(5): 420-424.
[3]	XU Ting, YAN Feifei, ZHANG Chunhui, ZHANG Yanqiao. Analysis of clinical pathology and prognosis in patients with gastric cancer & bone metastasis [J]. Journal of Practical Oncology, 2019, 33(5): 436-441.
[4]	LI Siwei, PANG Da. Long non-coding RNA(lncRNA)role in cancer [J]. Journal of Practical Oncology, 2019, 33(5): 471-475.
[5]	QU Yanfei, LIU Chao, WANG Bojun, FANG Lin, ZHANG Yanqiao. Expression of CSN6 gene in hepatocellular carcinoma tissues and its clinical significance [J]. Journal of Practical Oncology, 2019, 33(4): 328-333.
[6]	LIU Jintao, GAO Ling, ZHOU Huiui. Expression of MAGEA4 and EB1 proteins in lung cancer tissues and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2019, 33(4): 334-339.
[7]	PU Rui, ZHU Lin, XIA Tingting, BI Haoran, SUN Hongru, HUANG Hao, ZHANG Lei, ZHAO Yashuang. Relationship between the methylation status of CpG island in STAT1,STAT3 gene promoters in peripheral blood and prognosis of colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(4): 346-351.
[8]	FANG Xuan, CHEN Hongsheng, Li Guodong, LIU Ming. Advances in research on treatment of aberrant crypt foci [J]. Journal of Practical Oncology, 2019, 33(4): 376-379.
[9]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[10]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[11]	BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.
[12]	SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.
[13]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[14]	TONG Guanghai, TIAN Yang, WU Huaxing. Application of lipidomics in colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 179-192.
[15]	LU Jiaoyun, ZHANG Qingyuan. Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 183-187.

Clinical relationship between PTPN9 expression and colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments